LifeMD (LFMD) – Investment Analysts’ Weekly Ratings Changes

LifeMD (NASDAQ: LFMD) recently received a number of ratings updates from brokerages and research firms:

• 8/7/2026 – LifeMD had its price target lowered by HC Wainwright from $10.00 to $9.00. They now have a “buy” rating on the stock.
• 8/6/2026 – LifeMD was given a new $5.00 price target by Lake Street Capital.
• 8/6/2026 – LifeMD was given a new $7.00 price target by Mizuho.
• 8/6/2026 – LifeMD had its price target lowered by B. Riley Financial, Inc. from $10.00 to $8.00. They now have a “buy” rating on the stock.
• 8/6/2026 – LifeMD had its price target lowered by BTIG Research from $10.00 to $9.00. They now have a “buy” rating on the stock.
• 8/4/2026 – LifeMD had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 7/18/2026 – LifeMD was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – LifeMD was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/20/2026 – LifeMD was upgraded by Wall Street Zen from “sell” to “hold”.

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.